Tercica’s Somatuline Depot approved for acromegaly
Executive Summary
Somatuline Depot (lanreotide) will launch in approximately two months, Tercica says following FDA's Aug. 30 approval for treatment of acromegaly in patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy is not an option. The company is aiming to achieve $100 million in sales by 2010, which, based on a target market of 4,000 patients, would translate to pricing in the range of $25,000 per patient. Somatuline Depot will compete with Novartis' long-acting treatment Sandostatin LAR (octreotide), which accounts for the majority of the U.S. acromegaly market...
|
Somatuline Depot (lanreotide) will launch in approximately two months, Tercica says following FDA's Aug. 30 approval for treatment of acromegaly in patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy is not an option. The company is aiming to achieve $100 million in sales by 2010, which, based on a target market of 4,000 patients, would translate to pricing in the range of $25,000 per patient. Somatuline Depot will compete with Novartis' long-acting treatment Sandostatin LAR (octreotide), which accounts for the majority of the U.S. acromegaly market.... |